What is AZN's current stock price?

AZN is currently trading at $204.20 with a daily change of -1.09%. Visit StocksRunner for live updates.

What are AZN stock's key strengths?

AZN current strengths include: Expands stock buyback program, Earnings are forecast to grow, Upgraded on attractively valued. These are updated in real time by the StocksRunner IQ algorithm.

What are the risks associated with AZN stock?

Current risk factors for AZN include: Low. Risk levels are assessed by StocksRunner based on volatility, sector strength, volume, and investor confidence.

What is AZN's current StocksRunner IQ Score?

AZN current StocksRunner IQ Score is: Strong Buy. This score reflects aggregated earnings data, news sentiment, analyst ratings, and market momentum as of the latest update.

What factors influence AZN's StocksRunner IQ Score?

AZN StocksRunner IQ Score is a composite Credibility Score that weighs: quarterly earnings results vs. analyst expectations, breaking news sentiment and headline credibility, Wall Street analyst price target consensus, trading volume and price momentum, and sector-level risk indicators. All factors are aggregated in real time.

<

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AZN Stock Analysis & IQ Rating | Astrazeneca

Q: Should I buy AZN stock right now?

StocksRunner does not provide personalized investment advice. Our IQ Credibility Score for AZN aggregates analyst sentiment, earnings performance, and news momentum to help you make an informed decision. The current IQ signal is: Strong Buy. Always consider your own risk tolerance and consult a financial advisor before investing.

Q: What does a Strong Buy rating mean for AZN?

A Strong Buy rating on StocksRunner indicates that the aggregated IQ score — drawing from earnings beats, analyst upgrades, and positive news sentiment — reflects high confidence in AZN near-term growth potential. It is the strongest signal in the StocksRunner IQ rating scale.

AZN

Astrazeneca

$204.20

-$2.25 | -1.09%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$212.71

MKT CAP

$645.76B

52W Low

$61.24

VOL

$1.34M

P/E Ratio

N/A

AVG VOL

$7.03M

RSI

81.59

TREND

Uptrend

AZN Stock IQ

Login to see Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AZN Target Price

Login to display

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Expands stock buyback program

AZN Price Performance

$94.23 (+116.70%)

$93.24 (+119.00%)

$74.13 (+175.46%)

$75.99 (+168.72%)

1year

6month

3month

1month

AZN Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

74%

Consensus Rating

100%

Buy
Opinion

17%

Trend
Score

91%

Potential
Score

AZN Street Sentiment is bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level

Risk Indicators

Investors losing confidence

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with events and the stock performance

74%

Positive

51 out of 69
events present

22%

Negative

15 out of 69
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$118.70

Resistance Price

N/A

Current Price Range

$204.20

$118.70

N/A

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Consensus Rating

STRONG BUY

7

Buy

0

Hold

0

Sell

Date

Action

Rating

Firm

Feb 03, 2026

Upgrade

Hold

Jan 29, 2026

Initiate

Buy

Citigroup

Dec 06, 2025

Reiterate

Overweight

JP Morgan

Nov 12, 2025

Reiterate

Buy

Jefferies

Nov 12, 2025

Reiterate

Overweight

JP Morgan

Runners Also Watch

Close Price

Change

PFE

Pfizer

26.65

-0.76%

HCM

HUTCHMED (China) Limited

15.29

+1.33%

TEVA

Teva Pharma

34.22

-0.29%

NVS

Novartis AG

162.67

-0.76%

ABT

Abbott Laboratories

112.21

+0.02%

AZN Latest Analysis +

FDA Approval For AbbVie/AstraZenecas Combination Treatment Could Set New Standard For Slow Growing Blood Cancer. On Friday the United States Food and Drug Administration (FDA) approved) for chronic lymphocytic leukemia (CLL).The FDA has approved the combination of Venclexta (venetoclax) and ) Calquence (acalabrutinib) as the first all-oral fixed-duration treatment for previously untreated patients with CLL a slow-growing blood cancer where the bone marrow produces too many dysfunctional B-lymph

Fri Feb 20, 2026

$204.20 | -1.09%

Activity

Why AstraZeneca PLC (AZN) is One of the Best Immunotherapy Stocks to Buy According to Hedge Funds.

Thu Feb 19, 2026

$208.77 | +0.13%

Potential

Ex-Dividend Reminder: Astrazeneca FS Specialty Lending Fund and Fortune Brands Innovations . Looking at the universe of stocks we cover at Dividend Channel on 2/20/26 Astrazeneca plc (Symbol: AZNCF) FS Specialty Lending Fund (Symbol: FSSL) and Fortune Brands Innovations Inc (Symbol: FBIN) will all trade ex-dividend for their respective upcoming dividends. Astrazenec

Wed Feb 18, 2026

$208.67 | -0.39%

Activity

Ex-Dividend Reminder: ONE Gas AstraZeneca and Regeneron Pharmaceuticals. Looking at the universe of stocks we cover at Dividend Channel on 2/20/26 ONE Gas Inc. (Symbol: OGS) AstraZeneca plc (Symbol: AZN) and Regeneron Pharmaceuticals Inc. (Symbol: REGN) will all trade ex-dividend for their respective upcoming dividends. ONE Gas Inc. will pay i

Wed Feb 18, 2026

$208.67 | -0.39%

Activity

Top 3 Health Care Stocks That May Collapse This Quarter. As of Feb. 18 2026 three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator which compares a stock’.s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’.s price action it can give traders a better sense of how a stock may perform in the short term. An as

Wed Feb 18, 2026

$208.67 | -0.39%

Activity

Earnings

Momentum

Technical

China charges former AstraZeneca executive – what it means for global pharmaceutical firms. AstraZenecas former China head has been formally charged with medical insurance fraud illegal trading and unlawful collection of personal information more than a year after he first came under investigation – casting a shadow over the Swedish-British drug makers expansion in its second-largest

Fri Feb 13, 2026

$205.55 | +0.50%

Activity

Big Deal Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca. After months of rumors drove up its share price the Chinese drug company has unveiled a record licensing deal with AstraZeneca only to see its stock tumble

image credit: Bamboo WorksGoing into the deal CSPC'.s earnings have been under pressure after its core drug business was hit by China'.s centralized procurement policiesThe company is accelerating its push into novel drugs fo

Thu Feb 12, 2026

$204.52 | -0.12%

Activity

Momentum

Potential

Heres How Much $100 Invested In AstraZeneca 5 Years Ago Would Be Worth Today. AstraZeneca (NYSE:) has outperformed the market over the past 5 years by 2.92% on an annualized basis producing an average annual return of 14.97%. Currently AstraZeneca has a market capitalization of $317.33 billion.

Wed Feb 11, 2026

$204.76 | +5.87%

Activity

Astras Ex-Chief in China Formally Charged With Insurance Fraud. AstraZeneca Plcs former China head Leon Wang has been formally charged with medical insurance fraud unlawful collection of personal information and illegal trade with the case heading to court.

Wed Feb 11, 2026

$204.76 | +5.87%

Activity

AstraZeneca awards $3.4 million to United States nonprofits to expand healthcare access.

Wed Feb 11, 2026

$204.76 | +5.87%

Activity

FAQ About AZN Stock Insights

What is AZN current stock price?

What are AZN stock strengths?

What is AZN Risk Level?

What is AZN market cap and volume?

What is AZN current Stock IQ?

Should I buy AZN stock right now?

Is AZN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AZN?

What does a 'Strong Sell' rating mean for AZN?

What factors influence AZN's Stock IQ?

Explore our AZN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AZN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AZN Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AZN

Astrazeneca

Set Alerts

Current Price

$204.20

-$2.25 | -1.09%

52W High

$212.71

MKT CAP

$645.76B

52W Low

$61.24

VOL

$1.34M

P/E Ratio

N/A

AVG VOL

$7.03M

RSI

81.59

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

PFE

Pfizer

26.65

-0.76%

HCM

HUTCHMED (China) Limited

15.29

+1.33%

TEVA

Teva Pharma

34.22

-0.29%

NVS

Novartis AG

162.67

-0.76%

ABT

Abbott Laboratories

112.21

+0.02%

AZN Price Performance

$94.23 (+116.70%)

$93.24 (+119.00%)

$74.13 (+175.46%)

$75.99 (+168.72%)

1year

6month

3month

1month

AZN Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

AZN Analysts opinion is positive and also has improved from the past 3 months

AZN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

74%

Consensus Rating

100%

Buy
Opinion

17%

Trend
Score

91%

Potential
Score

AZN Street Sentiment is bullish and have positive views on the near-term outlook

AZN Risk Level

AZN has Low risk level

Risk Indicators

Investors losing confidence

Low

LOW

HIGH

AZN Performance Sentiment

Sentiments overview associated with events and the stock performance.

74%

Positive

51 out of 69
events present

22%

Negative

15 out of 69
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support Price

$118.70

Resistance Price

N/A

Current Price Range

$204.20

$118.70

N/A

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Consensus Rating

STRONG BUY

7

Buy

0

Hold

0

Sell

Date

Action

Rating

Firm

Feb 03, 2026

Upgrade

Hold

Jan 29, 2026

Initiate

Buy

Citigroup

Dec 06, 2025

Reiterate

Overweight

JP Morgan

Nov 12, 2025

Reiterate

Buy

Jefferies

Nov 12, 2025

Reiterate

Overweight

JP Morgan

AZN Stock IQ

Login to unlock Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

AZN Rewards

Earnings are forecast to grow

AZN Rewards

Upgraded on attractively valued

AZN Rewards

Expands stock buyback program

AZN Latest Analysis

FDA Approval For AbbVie/AstraZenecas Combination Treatment Could Set New Standard For Slow Growing Blood Cancer. On Friday the United States Food and Drug Administration (FDA) approved) for chronic lymphocytic leukemia (CLL).The FDA has approved the combination of Venclexta (venetoclax) and ) Calquence (acalabrutinib) as the first all-oral fixed-duration treatment for previously untreated patients with CLL a slow-growing blood cancer where the bone marrow produces too many dysfunctional B-lymph

Fri Feb 20, 2026

$204.20 | -1.09%

Activity

Why AstraZeneca PLC (AZN) is One of the Best Immunotherapy Stocks to Buy According to Hedge Funds.

Thu Feb 19, 2026

$208.77 | +0.13%

Potential

Ex-Dividend Reminder: Astrazeneca FS Specialty Lending Fund and Fortune Brands Innovations . Looking at the universe of stocks we cover at Dividend Channel on 2/20/26 Astrazeneca plc (Symbol: AZNCF) FS Specialty Lending Fund (Symbol: FSSL) and Fortune Brands Innovations Inc (Symbol: FBIN) will all trade ex-dividend for their respective upcoming dividends. Astrazenec

Wed Feb 18, 2026

$208.67 | -0.39%

Activity

Ex-Dividend Reminder: ONE Gas AstraZeneca and Regeneron Pharmaceuticals. Looking at the universe of stocks we cover at Dividend Channel on 2/20/26 ONE Gas Inc. (Symbol: OGS) AstraZeneca plc (Symbol: AZN) and Regeneron Pharmaceuticals Inc. (Symbol: REGN) will all trade ex-dividend for their respective upcoming dividends. ONE Gas Inc. will pay i

Wed Feb 18, 2026

$208.67 | -0.39%

Activity

Top 3 Health Care Stocks That May Collapse This Quarter. As of Feb. 18 2026 three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator which compares a stock’.s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’.s price action it can give traders a better sense of how a stock may perform in the short term. An as

Wed Feb 18, 2026

$208.67 | -0.39%

Activity

Earnings

Momentum

Technical

China charges former AstraZeneca executive – what it means for global pharmaceutical firms. AstraZenecas former China head has been formally charged with medical insurance fraud illegal trading and unlawful collection of personal information more than a year after he first came under investigation – casting a shadow over the Swedish-British drug makers expansion in its second-largest

Fri Feb 13, 2026

$205.55 | +0.50%

Activity

Big Deal Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca. After months of rumors drove up its share price the Chinese drug company has unveiled a record licensing deal with AstraZeneca only to see its stock tumble

image credit: Bamboo WorksGoing into the deal CSPC'.s earnings have been under pressure after its core drug business was hit by China'.s centralized procurement policiesThe company is accelerating its push into novel drugs fo

Thu Feb 12, 2026

$204.52 | -0.12%

Activity

Momentum

Potential

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of AZN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AZN Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AZN Stock trends

AZN Stock performance

AZN Stock analysis

AZN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AZN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

AZN Stock Analysis & IQ Rating | Astrazeneca

AZN Stock IQ

AZN Target Price

AZN Analysts Opinion

AZN Street Sentiment

AZN Risk Level

AZN Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our AZN Stock insights

Receive our AZN Daily Alerts

AZN Street Sentiment

AZN Risk Level

Key Price Levels

Latest Analyst Actions

Discover AZN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of AZN. We're here to help you make informed investment decisions today.

Receive our AZN Daily Alerts

AZN Alerts